The C.A.M. Report
Complementary and Alternative Medicine: Fair, Balanced, and to the Point
  • About this web log

    This blog is intended as an objective and dispassionate source of information on the latest CAM research. Since my background is in pharmacy and allopathic medicine, I view all CAM as advancing through the development pipeline to eventually become integrated into mainstream medical practice. Some will succeed while others fail. But all are treated fairly here.

  • About the author

    John Russo, Jr., PharmD, is president of The MedCom Resource, Inc. Previously, he was senior vice president of medical communications at www.Vicus.com, a complementary and alternative medicine website.

  • Common sense considerations

    The material on this weblog is for informational purposes. It is not medical advice or counsel. Be smart, consult your health professional before using CAM.

  • Support this site

    If you found the information here helpful, please consider supporting this site.If you found the information here helpful, please consider supporting this site.

  • Recent Posts

  • Recent Comments

    Update on soy, isoflavones, and the risk of prostate cancer

    The effect of genistein, daidzein, miso soup, and soy food on the risk of prostate cancer differs based on the stage of the disease.

    Researchers at the National Cancer Center in Tokyo, Japan studied more than 43,000 Japanese adult men who generally have a high intake of isoflavones and a low incidence of prostate cancer.

    Here’s what they found.

    • No association between genistein, daidzein, miso soup, and soy food intake and total prostate cancer.
    • These 4 items decreased the risk of localized prostate cancer.
    • But there was a positive association between isoflavones and advanced prostate cancer.

    These results were strengthened when the analysis was confined to men older than 60 years where isoflavones and soy food were associated with a dose-dependent decrease in the risk of localized cancer.

    How can this be?

    An article in Doctors Guide says, “Once tumors lose estrogen-receptor beta expression and become aggressive, isoflavones may fail to protect against the development of advanced cancer, and might even increase the risk of progression, possibly by reducing serum testosterone.” It’s also possible that “advanced and localized prostate cancer may be different tumor subtypes, which may react differently to isoflavones.”

    A comparison of local and advanced prostate cancer plus other related information can be found at the Seattle Cancer Care Alliance website.

    3/23/07 21:02 JR

    Leave a Comment

    You must be logged in to post a comment.